Dimensional Fund Advisors LP grew its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 37.0% during the third quarter, according to its most recent filing with the SEC. The firm owned 539,784 shares of the biopharmaceutical company’s stock after acquiring an additional 145,649 shares during the period. Dimensional Fund Advisors LP owned about 0.24% of Alexion Pharmaceuticals worth $75,032,000 at the end of the most recent quarter.
Several other hedge funds have also recently bought and sold shares of the business. First Hawaiian Bank acquired a new stake in shares of Alexion Pharmaceuticals in the 3rd quarter worth $102,000. Columbia Asset Management acquired a new position in Alexion Pharmaceuticals during the third quarter worth about $138,000. Checchi Capital Advisers LLC acquired a new position in Alexion Pharmaceuticals during the third quarter worth about $204,000. K.J. Harrison & Partners Inc acquired a new position in Alexion Pharmaceuticals during the third quarter worth about $209,000. Finally, Bbva Compass Bancshares Inc. purchased a new stake in shares of Alexion Pharmaceuticals during the third quarter worth about $218,000. Hedge funds and other institutional investors own 93.31% of the company’s stock.
ALXN has been the subject of a number of recent analyst reports. Barclays boosted their target price on shares of Alexion Pharmaceuticals to $175.00 and gave the company an “overweight” rating in a report on Friday, September 28th. Credit Suisse Group set a $156.00 target price on shares of Alexion Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, September 25th. BidaskClub raised shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, September 29th. Zacks Investment Research cut shares of Alexion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, September 25th. Finally, Morgan Stanley upped their price target on shares of Alexion Pharmaceuticals from $157.00 to $165.00 and gave the company an “overweight” rating in a report on Thursday, October 11th. Three analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. Alexion Pharmaceuticals has a consensus rating of “Buy” and an average price target of $161.50.
Shares of ALXN opened at $109.53 on Tuesday. The company has a current ratio of 3.16, a quick ratio of 2.74 and a debt-to-equity ratio of 0.32. Alexion Pharmaceuticals, Inc. has a 1 year low of $102.10 and a 1 year high of $140.77. The stock has a market cap of $24.41 billion, a price-to-earnings ratio of 16.71, a P/E/G ratio of 0.94 and a beta of 1.01.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings results on Wednesday, October 24th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.74 by $0.28. The firm had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.02 billion. Alexion Pharmaceuticals had a return on equity of 16.60% and a net margin of 3.90%. The business’s quarterly revenue was up 19.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.44 EPS. As a group, equities analysts predict that Alexion Pharmaceuticals, Inc. will post 6.82 earnings per share for the current year.
In related news, EVP Indrani Lall Franchini sold 2,605 shares of the business’s stock in a transaction that occurred on Wednesday, November 28th. The stock was sold at an average price of $118.13, for a total transaction of $307,728.65. Following the transaction, the executive vice president now directly owns 29,304 shares of the company’s stock, valued at approximately $3,461,681.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.35% of the stock is owned by insiders.
Alexion Pharmaceuticals Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.
Featured Story: What are defining characteristics of a correction?
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.